Navigation Links
Therapure Biopharma Inc. opens for business with first client contracts
Date:9/3/2008

TORONTO, Sept. 3 /PRNewswire/ - Therapure Biopharma Inc., a Canadian biopharmaceutical company, announced that it is open for business and has its first contracts with customers in biopharmaceutical development and manufacturing.

Located in Mississauga, Ontario, just 30 minutes from Toronto's Pearson International Airport, Therapure Biopharma provides clients with customized solutions for the development and manufacture of complex biological products. Leveraging its unique and flexible, 130,000 square foot cGMP manufacturing facility, its extensive quality systems, and the dedication of its highly experienced staff, Therapure Biopharma is able to develop effective and innovative solutions to advance therapeutic proteins from the lab to the market.

"We are more than just a contract manufacturing organization (CMO)," said Thomas G. Wellner, President and Chief Executive Officer. "The Company's scientific, manufacturing, and downstream purification expertise, combined with an intimate understanding of advanced biology, complex proteins, and the regulatory requirements for biological drugs, enables us to be a drug development partner with our clients."

Therapure Biopharma offers a wide range of value-added services covering all aspects of protein production so that the scale-up to commercial manufacture will not be a barrier to success. The Company's qualified staff has solved many of the manufacturing challenges facing clients, and the Company will partner with clients to solve their challenges. Many dynamic companies have access to novel, high-value protein-based products that are ready for commercialization but do not have the capabilities to move ahead alone. Therapure Biopharma can help by applying a deep understanding of the market and the business opportunities for protein-based therapeutics.

"We understand the complex regulatory processes for the registration of biological products and have established quality-based cGMP compliant manufacturing processes. We also understand and appreciate the confidential nature of your business and desire a long-term relationship," said Mr. Wellner. "Therapure Biopharma is your one-stop shop for pilot and commercial scale protein/API production, processing, filling, and finishing. We can address your scale-up challenges from bench to commercial scale. Partner with us and we will apply our expertise and proprietary technology to advance your products effectively."

Let Therapure Biopharma be a partner in bringing your biopharmaceutical products to the world. For more information, please visit the company's website at http://www.therapurebio.com.


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
4. Ondine Biopharma Announces Second Quarter 2008 Financial Results
5. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
8. ARCA biopharma Appoints James Carr as Vice President of Marketing
9. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):